Menu
Location: Home page > Research > Research
Predictors of Major Adverse Cardiac Events (MACE) of ICIs-related Myocarditis Diagnosed in PUMCH
CopyFrom: PUMCH UpdateTime: 2022-09-23 Hits: 34 Font Size: SmallBig

Recently, the findings of the clinical research on immune checkpoint inhibitors (ICIs)-related myocarditis conducted by Professor Wang Mengzhao’s team from the Department of Respiratory and Critical Care Unit and Professor Wu Wei’s team from the Department of Cardiology of PUMCH were published in “Cancer Communications” (IF=15.283).

ICIs-related myocarditis has a low incidence rate but a high mortality rate, and there is a lack of targeted assessment and prediction methods and effective clinical management strategies for related catastrophic cardiac events. PUMCH irAEs Task Force, the PUMCH’s national multidisciplinary management and collaborative group for immune-related adverse events, led by Prof. Wang Mengzhao, diagnosed 52 patients with ICIs-related myocarditis, 23 of whom had at least one major adverse cardiac event (MACE), such as sudden cardiac death, cardiac arrest, cardiogenic shock, and complete atrioventricular block.

Through a retrospective multicenter study of the diagnosis and treatment of patients with ICIs-related myocarditis, the research team found that dynamic changes of the ST segment and T wave, ventricular arrhythmias, second- and third-degree AV block on ECG and new ventricular wall motion abnormalities indicated by echocardiography are independent predictors of MACE, and the occurrence of such events is an independent risk factor for poor prognosis. The results of the study suggest that patients with these ECG and echocardiographic abnormalities should stay alert for the occurrence of MACE and be treated with intensive therapy to improve their prognosis. The study uses the ECG and echocardiography findings for analysis, which is more clinically significant and valuable for dissemination.

As a national guiding center for the diagnosis and treatment of intractable and critical diseases, PUMCH is one of the first hospitals in China to conduct clinical research on immune checkpoint inhibitors for treating malignant tumors. Over the years, the hospital has accumulated rich clinical experience in the management of immune-related adverse events. The PUMCH irAEs Task Force, led by the Department of Respiratory and Critical Care Unit, co-founded with more than ten departments in PUMCH and 33 oncology centers nationwide in July 2018, not only supports the safe application of immunotherapy in various departments in PUMCH, but also has provided remote multidisciplinary diagnosis and treatment for more than 500 patients across China.


Written by: Xu Yan from the Department of Respiratory and Critical Care Unit and Song Yanjun from the Department of Cardiology

Translator: Liu Haiyan

Editor: Wu Wei and Wang Yao